AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28394858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort 15-minute incubation ALA followed by blue light PDT with fractional CO2 laser (FxCO2)
Number of subjects: 0
Study 28394858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort 30-minute incubation ALA followed by blue light PDT with fractional CO2 laser (FxCO2)
Number of subjects: 0
Study 28394858 — intervention group
Group type: COMPARATOR
Intervention: Ultrashort 15-minute incubation ALA followed by blue light PDT without fractional CO2 laser (‐FxCO2)
Number of subjects: 0
Study 28394858 — intervention group
Group type: COMPARATOR
Intervention: Ultrashort 30-minute incubation ALA followed by blue light PDT without fractional CO2 laser (‐FxCO2)
Number of subjects: 0
Study 26287025 — intervention group
Group type: COMPARATOR
Intervention: Traditional inferior alveolar nerve block (IANB)
Number of subjects: 91
Study 26287025 — intervention group
Group type: COMPARATOR
Intervention: IANB with computer-controlled local anesthetic delivery (CCLAD)
Number of subjects: 91
Study 26287025 — intervention group
Group type: COMPARATOR
Intervention: Intraligamental anesthesia with CCLAD
Number of subjects: 91
Study 23549522 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val/Val alleles
Number of subjects: 78
Study 23549522 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val/Met alleles
Number of subjects: 78
Study 23549522 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups (including COMT Val/Val, Val/Met, and Met/Met)
Number of subjects: 78
Study 21631324 — intervention group
Group type: EXPERIMENTAL
Intervention: gp100:209‐217(210M) peptide vaccine plus interleukin‐2 (720,000 IU per kilogram of body weight per dose)
Number of subjects: 185
Study 21631324 — intervention group
Group type: COMPARATOR
Intervention: Interleukin‐2 alone (720,000 IU per kilogram of body weight per dose)
Number of subjects: 185
Study 21631324 — intervention group
Group type: EXPERIMENTAL
Intervention: gp100:209‐217(210M) peptide vaccine plus interleukin‐2
Number of subjects: 185
Study 21631324 — intervention group
Group type: COMPARATOR
Intervention: Interleukin‐2 alone
Number of subjects: 185
Study 19839745 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous TURBT and TURP (group A)
Number of subjects: 48
Study 19839745 — intervention group
Group type: COMPARATOR
Intervention: Separate sittings for TURBT and TURP (group B)
Number of subjects: 48
Study 16622705 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (n=11)
Number of subjects: 52
Study 16622705 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous resection under CT guidance (n=41)
Number of subjects: 52
Study 12477759 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (1-6 pmol/kg/min)
Number of subjects: 0
Study 12477759 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin A (6-50 pmol/kg/min)
Number of subjects: 0
Study 12477759 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (highest dose)
Number of subjects: 0
Study 12477759 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin A (highest dose)
Number of subjects: 0
Study 12477759 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 10951534 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 4 weeks
Number of subjects: 17
Study 10951534 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 17
Study 10951534 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study 8858463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ILd‐AmB (group A)
Number of subjects: 15
Study 8858463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ILd‐AmB (group B)
Number of subjects: 15
Study 1639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous lyophilized collagen sponge
Number of subjects: 72
Study 1639582 — intervention group
Group type: COMPARATOR
Intervention: Dextranomer
Number of subjects: 72
Study 6733006 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg)
Number of subjects: 12
Study 6733006 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol L.A. (160 mg)
Number of subjects: 12
Study 6733006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30965312 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow cuff (39.3 discomfort rating)
Number of subjects: 233
Study 30965312 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide cuff inflated to narrow cuff pressure (44 discomfort rating)
Number of subjects: 233
Study 30965312 — intervention group
Group type: COMPARATOR
Intervention: Wide cuff
Number of subjects: 233
Study 30051623 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐AN with LEAP
Number of subjects: 78
Study 30051623 — intervention group
Group type: COMPARATOR
Intervention: CBT‐AN alone
Number of subjects: 78
Study 27357182 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 50
Study 27357182 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 50
Study 24594972 — intervention group
Group type: EXPERIMENTAL
Intervention: Website only
Number of subjects: 143
Study 24594972 — intervention group
Group type: EXPERIMENTAL
Intervention: Website plus HCP support
Number of subjects: 143
Study 24594972 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143
Study 22628490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 350
Study 22628490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil (1.25 to 3.25 mg)
Number of subjects: 350
Study 22628490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil (3.5 to 16 mg)
Number of subjects: 350
Study 22628490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 19028384 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LE)
Number of subjects: 30
Study 19028384 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene (CC)
Number of subjects: 30
Study 19028384 — intervention group
Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 30
Study 17336501 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic training via CD‐ROM and two remote training sessions
Number of subjects: 12
Study 15653083 — intervention group
Group type: COMPARATOR
Intervention: 1-year exercise program (n=34)
Number of subjects: 111
Study 15653083 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion without pedicle screw instrumentation (n=37)
Number of subjects: 111
Study 15653083 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion with pedicle screw instrumentation (n=40)
Number of subjects: 111
Study 15653083 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients (combined instrumented and non-instrumented)
Number of subjects: 111
Study 15653083 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (1-year exercise program)
Number of subjects: 111
Study 15653083 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (SF-36)
Number of subjects: 111
Study 12165396 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine treatment for 24 weeks
Number of subjects: 32
Study 12165396 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 controls)
Number of subjects: 32
Study 10036338 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g liquid carbohydrate with 14.5 g encapsulated guar gum (FIB)
Number of subjects: 0
Study 10036338 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g liquid carbohydrate (GLU)
Number of subjects: 0
Study 10036338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 0
Study 7671361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2046
Study 7671361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2046
Study 2085083 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium administered by a priming technique (0.1 mg/kg i.v. followed by 0.5 mg/kg after 6 min)
Number of subjects: 44
Study 2085083 — intervention group
Group type: COMPARATOR
Intervention: Atracurium bolus injection (0.6 mg/kg)
Number of subjects: 44
Study 464573 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin, vancomycin, and nystatin (GVN)
Number of subjects: 38
Study 464573 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and nystatin (GN)
Number of subjects: 38
Study 31961447 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 31961447 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 30375032 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile health based Preterm Home Care Program (mHealthPHCP) known as 'NeoRaksha' mobile health application
Number of subjects: 300
Study 30375032 — intervention group
Group type: COMPARATOR
Intervention: standard preterm care
Number of subjects: 300
Study 28476271 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician brief intervention for unhealthy alcohol use
Number of subjects: 3811
Study 28476271 — intervention group
Group type: COMPARATOR
Intervention: Non-physician providers and medical assistants intervention
Number of subjects: 3811
Study 26166595 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 24
Study 26166595 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 24
Study 22302619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-IOCv2 scores obtained from linear regression models
Number of subjects: 1828
Study 22302619 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression models for predicting IOCv2 items
Number of subjects: 1828
Study 21402241 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 21402241 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19735164 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 19735164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17721249 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (10-ml bolus followed by an infusion of 10 ml/h during 48 h)
Number of subjects: 42
Study 17721249 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo control)
Number of subjects: 42
Study 15090815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg twice a day
Number of subjects: 0
Study 15090815 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study 11419728 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized hazelnut extract
Number of subjects: 53
Study 11419728 — intervention group
Group type: COMPARATOR
Intervention: Commercially available hazelnut extract (Soluprick)
Number of subjects: 53
Study 11419728 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for milk
Number of subjects: 53
Study 11419728 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for egg
Number of subjects: 53
Study 11419728 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for wheat
Number of subjects: 53
Study 11419728 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for hazelnut
Number of subjects: 53
Study 11419728 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for cod
Number of subjects: 53
Study 9778665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (target plasma concentrations of 50, 100, 150, and 200 ng/ml)
Number of subjects: 10
Study 9778665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7820215 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement therapy
Number of subjects: 100
Study 2201729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (5 or 7.5 mg)
Number of subjects: 48
Study 2201729 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 or 0.25 mg)
Number of subjects: 48
Study 2201729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 414196 — intervention group
Group type: COMPARATOR
Intervention: Inhaled cromolyn sodium (Intal)
Number of subjects: 12
Study 414196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (Slo-Phyllin tablets, 7.5 mg/kg)
Number of subjects: 12
Study 30715250 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)-informed strategy (CRP ≥80 mg/L plus age/temperature-corrected tachypnea and/or chest indrawing)
Number of subjects: 1726
Study 30715250 — intervention group
Group type: COMPARATOR
Intervention: Current World Health Organization standard (respiratory rate ≥50 breaths/minute)
Number of subjects: 1726
Study 28715532 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 291
Study 28715532 — intervention group
Group type: COMPARATOR
Intervention: Non-carboplatin
Number of subjects: 291
Study 28715532 — intervention group
Group type: COMPARATOR
Intervention: Non-carboplatin (BRCA1/BRCA2 mutations)
Number of subjects: 291
Study 28715532 — intervention group
Group type: COMPARATOR
Intervention: Non-carboplatin (no BRCA1/BRCA2 mutations)
Number of subjects: 291
Study 28715532 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (no BRCA1/BRCA2 mutations)
Number of subjects: 291
Study 24874549 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention to reduce at-risk drinking
Number of subjects: 631
Study 24874549 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 631
Study 23557073 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout
Number of subjects: 1689
Study 23557073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1689
Study 22036191 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps
Number of subjects: 40
Study 22036191 — intervention group
Group type: COMPARATOR
Intervention: Cold biopsy forceps
Number of subjects: 40
Study 20109998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CPC mouth rinse
Number of subjects: 117
Study 20109998 — intervention group
Group type: COMPARATOR
Intervention: Fluoride mouth rinse
Number of subjects: 117
Study 22542612 — intervention group
Group type: EXPERIMENTAL
Intervention: GA combined with pre‐emptive nerve stimulator‐guided pudendal nerve block (PNB) with 10 mL of 0.25% bupivacaine on each side
Number of subjects: 130
Study 22542612 — intervention group
Group type: COMPARATOR
Intervention: GA alone
Number of subjects: 130
Study 16078390 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 0
Study 16078390 — intervention group
Group type: EXPERIMENTAL
Intervention: Common regulatory claims based on subgroup analyses
Number of subjects: 0
Study 12956499 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-based bruxism recording system
Number of subjects: 56
Study 10435232 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 260
Study 10435232 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-based intervention
Number of subjects: 260
Study 8001387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic technique
Number of subjects: 76
Study 8001387 — intervention group
Group type: COMPARATOR
Intervention: Traditional 'blind' technique (control)
Number of subjects: 76
Study 1691287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine 4 g/day (1 g q.i.d.) + Ribavirin 800 mg/day
Number of subjects: 15
Study 1691287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine 4 g/day (1 g q.i.d.) + Ribavirin 1200 mg/day
Number of subjects: 15
Study 1691287 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 1691287 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (Ribavirin and Isoprinosine)
Number of subjects: 15
Study 6779148 — intervention group
Group type: EXPERIMENTAL
Intervention: Persantine plus Aspirin (PR/A)
Number of subjects: 2026
Study 6779148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA)
Number of subjects: 2026
Study 6779148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLBO)
Number of subjects: 2026
Study 12190281 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 30
Study 12190281 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction
Number of subjects: 30
Study 12190281 — intervention group
Group type: COMPARATOR
Intervention: Self-guided instruction
Number of subjects: 30
Study 31116964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 7848
Study 31116964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7848
Study 29938584 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor recovery group (ARAT ≤9 points)
Number of subjects: 36
Study 29938584 — intervention group
Group type: COMPARATOR
Intervention: Good recovery group (ARAT ≥10 points)
Number of subjects: 36
Study 26716589 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 1315
Study 26716589 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1315
Study 24813558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus diet (n=32)
Number of subjects: 64
Study 24813558 — intervention group
Group type: COMPARATOR
Intervention: Diet only (n=32)
Number of subjects: 64
Study 22652276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to SEMT guidelines for medical history
Number of subjects: 1790
Study 22652276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to SEMT guidelines for physical examination
Number of subjects: 1790
Study 22652276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to SEMT guidelines for laboratory evaluations
Number of subjects: 1790
Study 22652276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall guideline adherence
Number of subjects: 1790
Study 22652276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence based on age and gender
Number of subjects: 1790
Study 22652276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence by institution type
Number of subjects: 1790
Study 20739720 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (1.66 g)
Number of subjects: 11
Study 20739720 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing added)
Number of subjects: 11
Study 20739720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nothing added, participants told they received taurine)
Number of subjects: 11
Study 17654298 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone booster sessions after intensive inpatient treatment
Number of subjects: 290
Study 17654298 — intervention group
Group type: COMPARATOR
Intervention: Standard group smoking cessation program without telephone booster sessions
Number of subjects: 290
Study 15941534 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation (vitamin A 600 microg, beta-carotene 1.0 mg, vitamin E 100 mg, vitamin C 300 mg, Na2SeO3 200 microg daily for 8 weeks)
Number of subjects: 82
Study 15941534 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo tablet)
Number of subjects: 82
Study 15941534 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation
Number of subjects: 82
Study 15941534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 12044624 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular opioids plus low dose intravenous ketamine (0.6 mg/kg)
Number of subjects: 35
Study 12044624 — intervention group
Group type: COMPARATOR
Intervention: Regular opioids plus placebo
Number of subjects: 35
Study 10442368 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel by 1-hour infusion plus UFT/oral calcium folinate
Number of subjects: 0
Study 10442368 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 8848885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with glucose 8% (H group)
Number of subjects: 40
Study 8848885 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% plain (P group)
Number of subjects: 40
Study 8848885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P and H)
Number of subjects: 40
Study 2349134 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg orally four times a day for 1 week
Number of subjects: 6
Study 2349134 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg orally four times a day for 1 week
Number of subjects: 6
Study 367411 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 75 to 300 mg
Number of subjects: 12
Study 367411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 25 mg
Number of subjects: 12
Study 367411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 100 mg
Number of subjects: 12
Study 367411 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg + Cyclizine 50 mg
Number of subjects: 12
Study 367411 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg + Cyclizine 100 mg
Number of subjects: 12
Study 30507733 — intervention group
Group type: EXPERIMENTAL
Intervention: Back squats with PAP
Number of subjects: 10
Study 30690866 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with high sodium (150 meq/d)
Number of subjects: 412
Study 30690866 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with low sodium (50 meq/d)
Number of subjects: 412
Study 30690866 — intervention group
Group type: COMPARATOR
Intervention: Typical Western diet (control)
Number of subjects: 412
Study 28072706 — intervention group
Group type: EXPERIMENTAL
Intervention: GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30‐minute intravenous infusion weekly for 3 weeks followed by a 1‐week break every 4 weeks)
Number of subjects: 214
Study 28072706 — intervention group
Group type: COMPARATOR
Intervention: Gem (by 30‐minute intravenous infusion weekly for 3 weeks every 4 weeks)
Number of subjects: 214
Study 28072706 — intervention group
Group type: EXPERIMENTAL
Intervention: GemCap
Number of subjects: 214
Study 28072706 — intervention group
Group type: COMPARATOR
Intervention: Gem
Number of subjects: 214
Study 26468172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and exercise
Number of subjects: 49